2017, Number 4
<< Back Next >>
Acta Med 2017; 15 (4)
Age-related macular degeneration
Harrison GC, Domínguez CLG
Language: Spanish
References: 5
Page: 312-313
PDF size: 161.71 Kb.
Text Extraction
No abstract.
REFERENCES
Fong DS. Age-related macular degeneration: update for primary care. Am Fam Physician. 2000; 61: 3035-3042.
Chakravarthy U, Wong TY, Fletcher A, Piault E, Evans C, Zlateva G et al. Clinical risk factors for age-related macular degeneration: a systematic review and meta-analysis. BMC Ophthalmol. 2010; 10: 31.
Fung EA, Lalwani AG, Rosenfeld JP, Dubovy RS, Michels S, Feuer WJ et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophtalmology. 2007; 143 (4): 566-583.
Brechner RJ, Rosenfeld PJ, Babish JD, Caplan S. Pharmacotherapy for neovascular age-related macular degeneration: an analysis of the 100% 2008 medicare fee-for-service part B claims file. Am J Ophthalmol. 2011; 151: 887-895.
Berg K, Hadzalic E, Gjertsen I, Forsaa V, Berger LH, Kinge B et al. Ranibizumab or bevacizumab for neovascular age-related macular degeneration according to the lucentis compared to avastin study treat-and-extend protocol: two-year result. Ophtalmology. 2016; 123: 51-59.
Full text